{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T10:53:19Z","timestamp":1758970399866},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2015,8,5]],"date-time":"2015-08-05T00:00:00Z","timestamp":1438732800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1007\/s40264-015-0332-6","type":"journal-article","created":{"date-parts":[[2015,8,4]],"date-time":"2015-08-04T12:46:08Z","timestamp":1438692368000},"page":"1127-1139","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Safety of Perflutren Ultrasound Contrast Agents: A Disproportionality Analysis of the US FAERS Database"],"prefix":"10.1007","volume":"38","author":[{"given":"Manfred","family":"Hauben","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric Y.","family":"Hung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly C.","family":"Hanretta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sripal","family":"Bangalore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenza","family":"Snow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,8,5]]},"reference":[{"issue":"5","key":"332_CR1","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1016\/0735-1097(93)90562-F","volume":"22","author":"LJ Crouse","year":"1993","unstructured":"Crouse LJ, Cheirif J, Hanly DE, Kisslo JA, Labovitz AJ, Raichlen JS, Schutz RW, Shah PM, Smith MD. Opacification and border delineation improvement in patients with suboptimal endocardial border definition in routine echocardiography: results of the Phase III Albunex Multicenter Trial. J Am Coll Cardiol. 1993;22(5):1494\u2013500.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"332_CR2","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0735-1097(99)00558-6","volume":"35","author":"JP Reilly","year":"2000","unstructured":"Reilly JP, Tunick PA, Timmermans RJ, Stein B, Rosenzweig BP, Kronzon I. Contrast echocardiography clarifies uninterpretable wall motion in intensive care unit patients. J Am Coll Cardiol. 2000;35(2):485\u201390.","journal-title":"J Am Coll Cardiol"},{"key":"332_CR3","unstructured":"US Food and Drug Administration, revised prescribing information for Definity on August 2011. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/021064s011lbl.pdf . Accessed 3 Jun 2015."},{"key":"332_CR4","unstructured":"US Food and Drug Administration, revised prescribing information for Optison on August 17, 2012. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/020899s015lbl.pdf . Accessed 3 Jun 2015."},{"issue":"3","key":"332_CR5","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1067\/mje.2000.103597","volume":"13","author":"EH Yu","year":"2000","unstructured":"Yu EH, Sloggett CE, Iwanochko RM, Rakowski H, Siu SC. Feasibility and accuracy of left ventricular volumes and ejection fraction determination by fundamental, tissue harmonic, and intravenous contrast imaging in difficult-to-image patients. J Am Soc Echocardiogr. 2000;13(3):216\u201324.","journal-title":"J Am Soc Echocardiogr"},{"issue":"5","key":"332_CR6","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.jacc.2004.05.068","volume":"44","author":"S Malm","year":"2004","unstructured":"Malm S, Frigstad S, Sagberg E, Larsson H, Skjaerpe T. Accurate and reproducible measurement of left ventricular volume and ejection fraction by contrast echocardiography: a comparison with magnetic resonance imaging. J Am Coll Cardiol. 2004;44(5):1030\u20135.","journal-title":"J Am Coll Cardiol"},{"key":"332_CR7","unstructured":"U.S. Food and Drug Administration Alert. Micro-bubble contrast agents (marketed as Definity (Perflutren Lipid Microsphere) Injectable Suspension and Optison (Perflutren Protein-Type A Microspheres for Injection). 2007. http:\/\/www.fda.gov\/Safety\/MedWatch\/SafetyInformation\/SafetyAlertsforHumanMedicalProducts\/ucm152686.htm . Accessed 3 Jun 2015."},{"key":"332_CR8","unstructured":"US Food and Drug Administration, FDA Advisory Committee Briefing Document, Cardiovascular and Renal Drugs Advisory Committee June 24, 2008, Safety considerations in the development of ultrasound contrast agents. http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/08\/briefing\/2008-4369b1-01.pdf . Accessed 3 Jun 2015."},{"issue":"1","key":"332_CR9","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1517\/14740330802658581","volume":"8","author":"ML Main","year":"2009","unstructured":"Main ML, Goldman JH, Grayburn PA. Ultrasound contrast agents: balancing safety versus efficacy. Exp Opin Drug Saf. 2009;8(1):49\u201356.","journal-title":"Exp Opin Drug Saf"},{"key":"332_CR10","first-page":"376","volume":"29","author":"YM Smyth","year":"2008","unstructured":"Smyth YM, Gabriel RS, Sabik EM, Klein AL, Grimm R, Thomas JD, Menon V. Marked decline in clinical use of ultrasound contrast agents following black box warning: observations from the clinic. Eur Heart J. 2008;29:376.","journal-title":"Eur Heart J"},{"key":"332_CR11","unstructured":"Summary Minutes of May 2, 2011 Joint Meeting of the Cardiovascular and Renal Drugs and Drug Safety and Risk Management Advisory Committees. http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/CardiovascularandRenalDrugsAdvisoryCommittee\/UCM255248.pdf . Accessed 3 Jun 2015."},{"issue":"7","key":"332_CR12","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.echo.2012.04.002","volume":"25","author":"RJ Weiss","year":"2012","unstructured":"Weiss RJ, Ahmad M, Villanueva F, Schmitz S, Bhat G, Hibberd MG, Main ML. CaRES (Contrast Echocardiography Registry for Safety Surveillance): a prospective multicenter study to evaluate the safety of the ultrasound contrast agent definity in clinical practice. J Am Soc Echocardiogr. 2012;25(7):790\u20135.","journal-title":"J Am Soc Echocardiogr"},{"issue":"5","key":"332_CR13","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.echo.2012.01.019","volume":"25","author":"K Wei","year":"2012","unstructured":"Wei K, Main ML, Lang RM, Klein A, Angeli S, Panetta C, Mikati I, Lee LV, Bernstein JA, Ahmad M. The effect of definity on systemic and pulmonary hemodynamics in patients. J Am Soc Echocardiogr. 2012;25(5):584\u20138.","journal-title":"J Am Soc Echocardiogr"},{"issue":"6","key":"332_CR14","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.jcmg.2010.04.006","volume":"3","author":"A Exuzides","year":"2010","unstructured":"Exuzides A, Main ML, Colby C, Grayburn PA, Feinstein SB, Goldman JH. A retrospective comparison of mortality in critically ill hospitalized patients undergoing echocardiography with and without ultrasound contrast. JACC Cardiovasc Imaging. 2010;3(6):578\u201385.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"1","key":"332_CR15","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jacc.2008.08.066","volume":"53","author":"MS Dolan","year":"2009","unstructured":"Dolan MS, Gala SS, Dodla S, Abdelmoneim SS, Xie F, Cloutier D, Bierig M, Mulvagh SL, Porter TR, Labovitz AJ. Safety and efficacy of commercially available ultrasound contrast agents for rest and stress echocardiography a multicenter experience. J Am Coll Cardiol. 2009;53(1):32\u20138.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"332_CR16","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.amjcard.2008.06.066","volume":"102","author":"RS Gabriel","year":"2008","unstructured":"Gabriel RS, Smyth YM, Menon V, Klein AL, Grimm RA, Thomas JD, Sabik EM. Safety of ultrasound contrast agents in stress echocardiography. Am J Cardiol. 2008;102(9):1269\u201372.","journal-title":"Am J Cardiol"},{"issue":"17","key":"332_CR17","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1001\/jama.299.17.2023","volume":"299","author":"CA Herzog","year":"2008","unstructured":"Herzog CA. Incidence of adverse events associated with use of perflutren contrast agents for echocardiography. JAMA. 2008;299(17):2023\u20135.","journal-title":"JAMA"},{"issue":"5","key":"332_CR18","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.amjcard.2010.04.034","volume":"106","author":"OA Khawaja","year":"2010","unstructured":"Khawaja OA, Shaikh KA, Al-Mallah MH. Meta-analysis of adverse cardiovascular events associated with echocardiographic contrast agents. Am J Cardiol. 2010;106(5):742\u20137.","journal-title":"Am J Cardiol"},{"issue":"17","key":"332_CR19","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.jacc.2008.03.006","volume":"51","author":"LL Kusnetzky","year":"2008","unstructured":"Kusnetzky LL, Khalid A, Khumri TM, Moe TG, Jones PG, Main ML. Acute mortality in hospitalized patients undergoing echocardiography with and without an ultrasound contrast agent: results in 18,671 consecutive studies. J Am Coll Cardiol. 2008;51(17):1704\u20136.","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"332_CR20","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/j.amjcard.2008.08.019","volume":"102","author":"ML Main","year":"2008","unstructured":"Main ML, Ryan AC, Davis TE, Albano MP, Kusnetzky LL, Hibberd M. Acute mortality in hospitalized patients undergoing echocardiography with and without an ultrasound contrast agent (multicenter registry results in 4,300,966 consecutive patients). Am J Cardiol. 2008;102(12):1742\u20136.","journal-title":"Am J Cardiol"},{"issue":"11","key":"332_CR21","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.echo.2008.07.019","volume":"21","author":"K Wei","year":"2008","unstructured":"Wei K, Mulvagh SL, Carson L, et al. The safety of Definity and Optison for ultrasound image enhancement: a retrospective analysis of 78,383 administered contrast doses. J Am Soc Echocardiogr. 2008;21(11):1202\u20136.","journal-title":"J Am Soc Echocardiogr"},{"issue":"12","key":"332_CR22","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1136\/hrt.2007.135145","volume":"94","author":"C Aggeli","year":"2008","unstructured":"Aggeli C, Giannopoulos G, Roussakis G, Christoforatou E, Marinos G, Toli C, Pitsavos C, Stefanadis C. Safety of myocardial flash-contrast echocardiography in combination with dobutamine stress testing for detection of ischemia in 5250 studies. Heart. 2008;94(12):1571\u20137.","journal-title":"Heart"},{"issue":"12","key":"332_CR23","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.hlc.2013.05.637","volume":"22","author":"DG Platts","year":"2013","unstructured":"Platts DG, Luis SA, Roper D, Burstow D, Call T, Forshaw A, Pascoe R. The safety profile of perflutren microsphere contrast echocardiography during rest and stress imaging: results from an Australian multicentre cohort. Heart Lung Circ. 2013;22(12):996\u20131002.","journal-title":"Heart Lung Circ"},{"issue":"3","key":"332_CR24","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1161\/CIRCIMAGING.109.895029","volume":"3","author":"SS Abdelmoneim","year":"2010","unstructured":"Abdelmoneim SS, Bernier M, Scott CG, Dhoble A, Ness SA, Hagen ME, Moir S, McCully RB, Pellikka PA, Mulvagh SL. Safety of contrast agent use during stress echocardiography in patients with elevated right ventricular systolic pressure: a cohort study. Circ Cardiovasc Imaging. 2010;3(3):240\u20138.","journal-title":"Circ Cardiovasc Imaging"},{"issue":"9","key":"332_CR25","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.jcmg.2009.03.020","volume":"2","author":"SS Abdelmoneim","year":"2009","unstructured":"Abdelmoneim SS, Bernier M, Scott CG, Dhoble A, Ness SA, Hagen ME, Moir S, McCully RB, Pellikka PA, Mulvagh SL. Safety of contrast agent use during stress echocardiography: a 4-year experience from a single-center cohort study of 26,774 patients. JACC Cardiovasc Imaging. 2009;2(9):1048\u201356.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"11","key":"332_CR26","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.amjcard.2008.07.032","volume":"102","author":"K Shaikh","year":"2008","unstructured":"Shaikh K, Chang SM, Peterson L, Rosendahl-Garcia K, Quinones MA, Nagueh SF, Kurrelmeyer K, Zoghbi WA. Safety of contrast administration for endocardial enhancement during stress echocardiography compared with noncontrast stress. Am J Cardiol. 2008;102(11):1444\u201350.","journal-title":"Am J Cardiol"},{"issue":"1","key":"332_CR27","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.amjcard.2009.02.041","volume":"104","author":"B Anantharam","year":"2009","unstructured":"Anantharam B, Chahal N, Chelliah R, Ramzy I, Gani F, Senior R. Safety of contrast in stress echocardiography in stable patients and in patients with suspected acute coronary syndrome but negative 12-hour troponin. Am J Cardiol. 2009;104(1):14\u20138.","journal-title":"Am J Cardiol"},{"issue":"7","key":"332_CR28","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/jcph.84","volume":"53","author":"M Hauben","year":"2013","unstructured":"Hauben M, Hung EY. A quantitative analysis of the spontaneous reporting of congestive heart failure-related adverse events with systemic anti-fungal drugs. J Clin Pharmacol. 2013;53(7):762\u201372.","journal-title":"J Clin Pharmacol"},{"issue":"8","key":"332_CR29","doi-asserted-by":"crossref","first-page":"965","DOI":"10.7150\/ijms.5377","volume":"10","author":"M Hauben","year":"2013","unstructured":"Hauben M, Hung EY. Pneumothorax as an adverse drug event: an exploratory aggregate analysis of the US FDA AERS database including a confounding by indication analysis inspired by Cornfield\u2019s condition. Int J Med Sci. 2013;10(8):965\u201373.","journal-title":"Int J Med Sci"},{"key":"332_CR30","unstructured":"FDA adverse event reporting system. http:\/\/www.fda.gov\/drugs\/guidancecomplianceregulatoryinformation\/surveillance\/adversedrugeffects\/default.htm . Accessed 3 Jun 2015."},{"key":"332_CR31","unstructured":"MedDRA\u00ae Maintenance and Support Services Organization. Introductory guide for Standardised MedDRA\u00ae Queries (SMQs) Version 17.0. 2014. http:\/\/www.meddra.org\/sites\/default\/files\/guidance\/file\/smq_intguide_17_0_english.pdf . Accessed 3 Jun 2015."},{"issue":"6","key":"332_CR32","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2165\/00002018-200225060-00009","volume":"25","author":"EG Brown","year":"2002","unstructured":"Brown EG. Effects of coding dictionary on signal generation: a consideration of use of MedDRA compared with WHO-ART. Drug Saf. 2002;25(6):445\u201352.","journal-title":"Drug Saf"},{"issue":"7\u20138","key":"332_CR33","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.drudis.2008.12.012","volume":"14","author":"M Hauben","year":"2009","unstructured":"Hauben M, Bate A. Decision support methods for the detection of adverse events in post-marketing data. Drug Discov Today. 2009;14(7\u20138):343\u201357.","journal-title":"Drug Discov Today"},{"issue":"2","key":"332_CR34","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2165\/00002018-200932020-00003","volume":"32","author":"M Hauben","year":"2009","unstructured":"Hauben M, Aronson JK. Defining \u2018signal\u2019 and its subtypes in pharmacovigilance based on a systematic review of previous definitions. Drug Saf. 2009;32(2):99\u2013110.","journal-title":"Drug Saf"},{"issue":"6","key":"332_CR35","first-page":"307","volume":"13","author":"K Kubota","year":"2004","unstructured":"Kubota K, Koide D, Toshiki H. Comparison of data mining methodologies using Japanese spontaneous reports. Pharamcoepidemiol Drug Saf. 2004;13(6):307\u201394.","journal-title":"Pharamcoepidemiol Drug Saf"},{"issue":"2","key":"332_CR36","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/pds.3529","volume":"23","author":"F Maignon","year":"2014","unstructured":"Maignon F, Hauben M, Hung E, VanHolle L, Dogne JM. Assessing the extent and impact of the masking effect of disproportionality analyses on two spontaneous reporting systems databases. Pharmacoepidemiol Drug Saf. 2014;23(2):195\u2013207.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"11","key":"332_CR37","doi-asserted-by":"crossref","first-page":"981","DOI":"10.2165\/00002018-200528110-00002","volume":"28","author":"J Almenoff","year":"2005","unstructured":"Almenoff J, Tonning JM, Gould AL, Szarfman A, Hauben M, Ouellet-Hellstrom R, Ball R, Hornbuckle K, Walsh L, Yee C, Sacks ST, Yuen N, Patadia V, Blum M, Johnston M, Gerrits C, Seifert H, Lacroix K. Perspectives on the use of data mining in pharmacovigilance. Drug Saf. 2005;28(11):981\u20131007.","journal-title":"Drug Saf"},{"key":"332_CR38","unstructured":"EMEA Eudravigilance Expert Working Group (EV-EWG). Guideline on the use of statistical signal detection methods in the Eudravigilance data analysis system. 26 June 2008. London. Doc. Ref. EMEA\/106464\/2006 rev.1. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Regulatory_and_procedural_guideline\/2009\/11\/WC500011434.pdf . Accessed 3 Jun 2015."},{"key":"332_CR39","unstructured":"Zhao J, Karlsson I, Asker L, Bostr\u00f6m H. Applying methods for signal detection in spontaneous reports to electronic patient records. In: Proceedings of the ACM KDD; 2013."},{"issue":"6","key":"332_CR40","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/pds.1742","volume":"18","author":"A Bate","year":"2009","unstructured":"Bate A, Evans SJ. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009;18(6):427\u201336.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"332_CR41","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1378\/chest.120.4.1287","volume":"120","author":"TT Nguyen","year":"2001","unstructured":"Nguyen TT, Dhond MR, Sabapathy R, Bommer WJ. Contrast microbubbles improve diagnostic yield in ICU patients with poor echocardiographic windows. Chest. 2001;120(4):1287\u201392.","journal-title":"Chest"},{"issue":"8","key":"332_CR42","doi-asserted-by":"crossref","first-page":"645","DOI":"10.2165\/00002018-200730080-00001","volume":"30","author":"M Hauben","year":"2007","unstructured":"Hauben M, Aronson JK. Gold standards in pharmacovigilance: the use of definitive anecdotal reports of adverse drug reactions as pure gold and high-grade ore. Drug Saf. 2007;30(8):645\u201355.","journal-title":"Drug Saf"},{"issue":"7581","key":"332_CR43","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1136\/bmj.39036.666389.94","volume":"333","author":"JK Aronson","year":"2006","unstructured":"Aronson JK, Hauben M. Anecdotes that provide definitive evidence. BMJ. 2006;333(7581):1267\u20139.","journal-title":"BMJ"},{"issue":"9","key":"332_CR44","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1002\/pds.3622","volume":"23","author":"P deBoissieu","year":"2014","unstructured":"deBoissieu P, Kanagaratnam L, Abou Taam M, Roux MP, Drame M, Trenque T. Notoriety bias in a database of spontaneous reports: the example of osteonecrosis of the jaw under bisphosphonate therapy in the French national pharmacovigilance database. Pharmacoepidemiol Drug Saf. 2014;23(9):989\u201392.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"11","key":"332_CR45","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1002\/pds.2022","volume":"19","author":"A Pariente","year":"2010","unstructured":"Pariente A, Didailler M, Avillach P, Miremont-Salame G, Fourrier-Regalt A, Haramburu F, Moore N. A potential competition bias in the detection of safety signals from spontaneous reporting databases. Pharmacoepidemiol Drug Saf. 2010;19(11):1166\u201371.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"332_CR46","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/pds.848","volume":"12","author":"N Moore","year":"2003","unstructured":"Moore N, Hall G, Sturkenboom M, Mann R, Lagnaoui R, Begaud B. Biases affecting the proportional reporting ratio (PRR) in spontaneous reports pharmacovigilance databases: the example of sertindole. Pharmacoepidemiol Drug Saf. 2003;12(4):271\u201381.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"332_CR47","doi-asserted-by":"crossref","first-page":"551","DOI":"10.2165\/00002018-200730060-00009","volume":"30","author":"M Hauben","year":"2007","unstructured":"Hauben M, Reich L, DeMicco J, Kim K. \u201cExtreme duplication\u201d in the US FDA adverse events reporting system database. Drug Saf. 2007;30(6):551\u20134.","journal-title":"Drug Saf"},{"issue":"3","key":"332_CR48","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/j.1742-7843.2006.pto_232.x","volume":"98","author":"A Bate","year":"2006","unstructured":"Bate A, Edwards IR. Data mining in spontaneous reports. Basic Clin Pharmacol Toxicol. 2006;98(3):324\u201330.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"5","key":"332_CR49","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s00228-007-0279-3","volume":"63","author":"M Hauben","year":"2007","unstructured":"Hauben M, Reich L, Gerrits CM, Younus M. Illusions of objectivity and recommendation for reporting data mining results. Eur J Clin Pharmacol. 2007;63(5):517\u201321.","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"332_CR50","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1198\/000313001317097960","volume":"55","author":"N Schenker","year":"2001","unstructured":"Schenker N, Gentleman JF. On judging the significance of differences by examining the overlap between confidence intervals. Am Stat. 2001;55(3):182\u20136.","journal-title":"Am Stat"},{"issue":"12","key":"332_CR51","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1345\/aph.1L315","volume":"42","author":"Y Chen","year":"2008","unstructured":"Chen Y, Guo JJ, Healy DP, Lin X, Patel NC. Risk of hepatotoxicity associated with the use of telithromycin: a signal detection using data mining algorithms. Ann Pharmacother. 2008;42(12):1791\u20136.","journal-title":"Ann Pharmacother"},{"issue":"1","key":"332_CR52","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/19466315.2014.1002628","volume":"7","author":"M Hauben","year":"2015","unstructured":"Hauben M, Zou C, Whalen E, Wang W, Zhang LH. A pilot study on the feasibility of using P-plots for signal detection in pharmacovigilance. Stat Biopharm Res. 2015;7(1):25\u201335.","journal-title":"Stat Biopharm Res"},{"issue":"23","key":"332_CR53","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1093\/bioinformatics\/bts576","volume":"28","author":"K Johnson","year":"2012","unstructured":"Johnson K, Guo C, Gosink M, Wang V, Hauben M. Multinomial modeling and an evaluation of common data-mining algorithms for identifying signals of disproportionate reporting in pharmacovigilance databases. Bioinformatics. 2012;28(23):3123\u201330.","journal-title":"Bioinformatics"},{"issue":"2","key":"332_CR54","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1214\/ss\/1063994981","volume":"18","author":"S Holmes","year":"2003","unstructured":"Holmes S, Morris C, Tibshirani R. Bradley Efron: a conversation with good friends. Stat Sci. 2003;18(2):268\u201382.","journal-title":"Stat Sci"},{"issue":"7","key":"332_CR55","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda T, Tamon A, Kadoyama K, Okuno Y. Data mining of the public version of the FDA Adverse Event Reporting System. Int J Med Sci. 2013;10(7):796\u2013803.","journal-title":"Int J Med Sci"},{"issue":"6","key":"332_CR56","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s40264-015-0289-5","volume":"38","author":"G Candore","year":"2015","unstructured":"Candore G, Juhlin K, Manlik K, Thakrat B, Quarcoo N, Seabroke S, Wisniewski A, Slattery J. Comparison of statistical signal detection methods within and across spontaneous reporting system databases. Drug Saf. 2015;38(6):577\u201387.","journal-title":"Drug Saf"},{"issue":"1","key":"332_CR57","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/pst.1657","volume":"14","author":"P Ghosh","year":"2015","unstructured":"Ghosh P, Dewanji A. Effect of reporting bias in the analysis of spontaneous reporting data. Pharm Stat. 2015;14(1):20\u20135.","journal-title":"Pharm Stat"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-015-0332-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40264-015-0332-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-015-0332-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T19:41:36Z","timestamp":1559504496000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40264-015-0332-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,5]]},"references-count":57,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["332"],"URL":"https:\/\/doi.org\/10.1007\/s40264-015-0332-6","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,5]]}}}